Year archive

Evolva Holding SA — 2022 filings

All 20 regulatory filings released by Evolva Holding SA (EVE) in 2022, sourced directly from the official regulator.

20 Filings

2022 Period

2022 filings (20)

Filing	Released	Lang
Evolva launches its Natural Nootkatone Regulatory Filings	2022-12-14	English
Evolva statement to SER communication Legal Proceedings Report	2022-12-12	English
Evolva: Update on activities to boost Resveratrol Regulatory Filings	2022-11-29	English
Evolva receives approval for Veri-teTM Resveratrol for animal health in Brazil Regulatory Filings	2022-11-10	English
Evolva receives grant from US CDC in the amount of USD 540,000 Regulatory Filings	2022-10-21	English
Evolvas NootkaSHIELDTM insect repellent approved in Hong Kong Regulatory Filings	2022-10-11	English
Evolva business update: Continued good business momentum Earnings Release 9M 2022	2022-10-06	English
Evolva with record half-yearly sales and new mid-term plan Earnings Release H1 2022	2022-08-25	English
Evolva statement to SER communication Legal Proceedings Report	2022-08-23	English
Evolva with strong business momentum in 1H 2022, announcing targets of mid-term plan Earnings Release H1 2022	2022-07-26	English
Evolva successfully placed shares from authorized capital, raising CHF 6.3 million Share Issue/Capital Change	2022-05-24	English
Evolva business update: On track to reach 2022 guidance Regulatory Filings	2022-05-19	English
Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil M&A Activity	2022-05-12	English
Evolva shareholders approve all proposed resolutions at the Annual General Meeting 2022 AGM Information	2022-05-05	English
Evolva achieves important product-related milestones with global customer, triggering revenues of more than 20% of FY21 total revenues Earnings Release FY 2021	2022-04-20	English
Evolvas AGM postponed to May 5, 2022 / agenda remains unchanged AGM Information	2022-04-07	English
Evolvas Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items: AGM Information	2022-03-22	English
Evolva grew product-related revenue by 40% in 2021 Earnings Release FY 2021	2022-03-10	English
Carsten Daweritz remains CFO of Evolva Board/Management Information	2022-02-28	English
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization Board/Management Information	2022-02-08	English